Your browser is no longer supported. Please, upgrade your browser.
Settings
CLDX Celldex Therapeutics, Inc. daily Stock Chart
CLDX [NASD]
Celldex Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.20 Insider Own0.20% Shs Outstand127.53M Perf Week-0.65%
Market Cap390.24M Forward P/E- EPS next Y-1.03 Insider Trans0.00% Shs Float123.29M Perf Month-8.93%
Income-128.10M PEG- EPS next Q-0.28 Inst Own67.00% Short Float15.65% Perf Quarter-14.53%
Sales7.00M P/S55.75 EPS this Y3.40% Inst Trans-0.89% Short Ratio10.68 Perf Half Y-30.14%
Book/sh2.02 P/B1.51 EPS next Y5.50% ROA-40.50% Target Price6.50 Perf Year-26.62%
Cash/sh1.31 P/C2.34 EPS next 5Y- ROE-53.10% 52W Range2.85 - 5.13 Perf YTD-13.56%
Dividend- P/FCF- EPS past 5Y-2.20% ROI-50.10% 52W High-40.35% Beta2.84
Dividend %- Quick Ratio6.40 Sales past 5Y-6.00% Gross Margin- 52W Low7.37% ATR0.12
Employees205 Current Ratio6.40 Sales Q/Q15.40% Oper. Margin- RSI (14)37.33 Volatility3.89% 4.02%
OptionableYes Debt/Eq0.00 EPS Q/Q20.50% Profit Margin- Rel Volume1.05 Prev Close3.10
ShortableYes LT Debt/Eq0.00 EarningsMay 11 Payout- Avg Volume1.81M Price3.06
Recom2.30 SMA20-2.90% SMA50-6.35% SMA200-14.68% Volume1,898,481 Change-1.29%
Nov-07-16Initiated Aegis Capital Buy
Mar-08-16Downgrade Jefferies Buy → Hold
Mar-07-16Downgrade Wedbush Outperform → Neutral $4
Mar-07-16Downgrade Leerink Partners Outperform → Mkt Perform
Mar-07-16Downgrade Guggenheim Buy → Neutral
Mar-01-16Initiated H.C. Wainwright Buy $25
Aug-11-15Reiterated ROTH Capital Buy $43 → $39
Aug-11-15Reiterated Oppenheimer Outperform $45 → $42
Aug-11-15Reiterated Brean Capital Buy $35 → $31
Jun-02-15Reiterated WBB Securities Strong Buy $30 → $40
Nov-17-14Reiterated ROTH Capital Buy $40 → $43
Mar-04-14Reiterated Oppenheimer Outperform $40 → $36
Jul-08-13Reiterated Cantor Fitzgerald Buy $16 → $24
Mar-08-13Reiterated Cantor Fitzgerald Buy $13 → $16
Feb-26-13Reiterated Oppenheimer Outperform $10 → $13
Jan-10-13Reiterated Cantor Fitzgerald Buy $9 → $13
Oct-02-12Reiterated Oppenheimer Outperform $6 → $8
Sep-14-12Reiterated Cantor Fitzgerald Buy $7 → $9
Apr-04-12Initiated Cantor Fitzgerald Buy $7
Nov-02-11Reiterated Brean Murray Buy $16 → $14
May-26-17 09:31AM  Celldex's Immuno-Oncology Pipeline Continues to Impress Zacks
May-21-17 06:41AM  Better Buy: Celldex Therapeutics, Inc. vs. Agenus Inc. Motley Fool
May-18-17 07:44AM  3 Value Stocks for Bold Investors Motley Fool
May-17-17 05:01PM  Celldex Therapeutics to Present Clinical Results at 2017 ASCO Annual Meeting GlobeNewswire
May-10-17 10:30AM  Celldex (CLDX) Q1 Loss In Line, Revenues Beat, Shares Up Zacks
08:50AM  3 Stocks That Could Double Your Investment Motley Fool
May-09-17 05:41PM  Celldex Therapeutics, Inc.'s Collaboration with Bristol-Myers Squibb Key in First-Quarter Update Motley Fool
05:34PM  Celldex reports 1Q loss Associated Press
04:01PM  Celldex Reports First Quarter 2017 Results GlobeNewswire
May-02-17 11:33AM  Celldex Therapeutics (CLDX) Q1 Earnings: What's in Store? Zacks
Apr-23-17 02:03PM  Read This Before You Buy Biotech Stocks Motley Fool
Apr-21-17 07:30AM  Today's Research Reports on Biotech Stocks to Watch: Celldex Therapeutics and Spectrum Pharmaceuticals Accesswire
Apr-20-17 10:21AM  Eli Lilly (LLY) to Report Q1 Earnings: What's in the Cards? Zacks
10:16AM  What's in Store for Biogen (BIIB) this Earnings Season? Zacks
Apr-19-17 02:16PM  ETFs with exposure to Celldex Therapeutics, Inc. : April 19, 2017 Capital Cube
03:26AM  Why Is Celldex (CLDX) Down 4.4% Since the Last Earnings Report? Zacks
Apr-17-17 08:42AM  3 Cancer Drug Stocks That Could Make You Rich Motley Fool
Apr-15-17 12:02PM  3 Biotech Stocks to Buy on Sale Motley Fool
Apr-07-17 04:11PM  ETFs with exposure to Celldex Therapeutics, Inc. : April 7, 2017 Capital Cube
11:09AM  3 Stocks That Could Double Your Money Motley Fool
Apr-01-17 12:02PM  3 Top Stocks You've Been Overlooking Motley Fool
12:02PM  3 Top Stocks You've Been Overlooking at Motley Fool
Mar-31-17 09:30AM  Today's Research Reports on Stocks to Watch: Celldex Therapeutics and PDL BioPharma Accesswire
Mar-30-17 08:12AM  Celldex Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CLDX-US : March 30, 2017 Capital Cube
08:12AM  Celldex Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CLDX-US : March 30, 2017
Mar-27-17 03:52PM  ETFs with exposure to Celldex Therapeutics, Inc. : March 27, 2017 Capital Cube
03:52PM  ETFs with exposure to Celldex Therapeutics, Inc. : March 27, 2017
Mar-25-17 12:03PM  3 Stocks That Could Double Your Money at Motley Fool
Mar-21-17 09:25AM  Celldex Therapeutics, Inc. :CLDX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017 Capital Cube -5.93%
09:25AM  Celldex Therapeutics, Inc. :CLDX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017
Mar-20-17 10:01AM  Celldex Therapeutics, Inc. :CLDX-US: Earnings Analysis: 2016 By the Numbers : March 20, 2017
Mar-18-17 01:04PM  CELLDEX THERAPEUTICS, INC. Financials
Mar-17-17 08:10AM  Celldex Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CLDX-US : March 17, 2017
Mar-15-17 10:55AM  Celldex (CLDX) Shares Up as Q4 Loss Narrows; Sales Beat Zacks
12:58AM  Edited Transcript of CLDX earnings conference call or presentation 14-Mar-17 8:30pm GMT Thomson Reuters StreetEvents
Mar-14-17 06:23PM  Celldex Therapeutics, Inc. Ends Q4 With Plenty of Cash and Several Key Studies Progressing Motley Fool
06:23PM  Celldex Therapeutics, Inc. Ends Q4 With Plenty of Cash and Several Key Studies Progressing at Motley Fool
04:30PM  Celldex Therapeutics Inc Earnings and Corporate Strategy Call scheduled for 4:30 pm ET today
04:26PM  CELLDEX THERAPEUTICS, INC. Files SEC form 10-K, Annual Report
04:14PM  Celldex reports 4Q loss Associated Press
04:01PM  Celldex Provides Corporate Update and Reports Full Year 2016 Results GlobeNewswire
07:07AM  Q4 2016 Celldex Therapeutics Inc Earnings Release - After Market Close
Mar-12-17 07:21AM  3 Horrible Stocks for Retirees at Motley Fool
Mar-10-17 02:42PM  Better Buy: Agenus Inc. vs. Celldex Therapeutics at Motley Fool
Mar-09-17 09:15AM  Spectrum (SPPI) Q4 Loss Narrower than Expected, Sales Beat
Mar-08-17 09:30AM  Biotech and Pharmaceutical Stocks Fall on Pricing Concerns: Today's Research Reports on Celldex Therapeutics and Mast Therapeutics Accesswire
Mar-07-17 04:43PM  Celldex Therapeutics, Inc. Is Feeling Some Pressure Today -- Here's Why at Motley Fool -9.19%
Mar-06-17 11:03AM  Why Celldex Therapeutics Stock Gained 10% in February at Motley Fool
08:46AM  Celldex Therapeutics (CLDX) Q4 Earnings: What's in Store?
Mar-03-17 08:03AM  3 Stocks That Could Double Your Money at Motley Fool
Mar-01-17 04:05PM  CELLDEX THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure, F
04:01PM  Celldex Therapeutics Announces Appointment to Board of Directors GlobeNewswire
Feb-24-17 05:42PM  3 Biotech Long Shots: Boom Or Bust? at Motley Fool
Feb-23-17 07:44PM  Looking Back at David Gardner's Worst Stock Picks of the Past 3 Years at Motley Fool
Feb-13-17 02:45PM  Celldex Therapeutics Announces Upcoming Investor Presentations and 2016 Year-End Call GlobeNewswire
Feb-09-17 09:48AM  Why Celldex Therapeutics Stock Fell by Almost 10% in January at Motley Fool
Feb-07-17 04:04PM  CELLDEX THERAPEUTICS, INC. Files SEC form 8-K/A, Completion of Acquisition or Disposition of Assets, Financial Statem
Feb-06-17 07:45AM  3 Stocks That Could Make You Rich at Motley Fool
Feb-03-17 09:30AM  Mergers & Acquisitions Could be a Key Catalyst for Biotech Stocks in 2017: Today's Reports on Cellect Biotechnology and Celldex Therapeutics Accesswire
Feb-01-17 08:14AM  Forget Celldex Therapeutics, Inc.: These 2 Stocks Are Better Buys at Motley Fool
Jan-30-17 03:12PM  3 Biotech Stocks I'd Buy Right Now at Motley Fool
Jan-26-17 04:28PM  5 Small-Cap Biotech Stocks to Buy in February at Motley Fool
Jan-20-17 10:41AM  3 Beaten-Down Biotech Stocks You Can Buy Right Now at Motley Fool
Jan-10-17 10:36AM  Celldex Therapeutics, Inc. Value Analysis (NASDAQ:CLDX) : January 10, 2017
09:09AM  Why Celldex Therapeutics Imploded in 2016 at Motley Fool
Jan-09-17 07:19AM  Celldex Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CLDX-US : January 9, 2017
Jan-06-17 01:26PM  Celldex Therapeutics, Inc.'s 3 Best Moves in 2016 at Motley Fool
Dec-24-16 02:52PM  Better Buy: Celldex Therapeutics, Inc. vs. Exelixis at Motley Fool
Dec-22-16 09:36AM  2016's Worst Clinical Failures at Motley Fool
09:24AM  2016 Was a Terrible Year for Biotech but the Tweets Were on Point
Dec-20-16 09:15AM  Latest Reports on Biotech Movers MannKind and Celldex Therapeutics Accesswire
Dec-19-16 02:51PM  How to Value Clinical-Stage Biotech Stocks at Motley Fool
07:18AM  Celldex Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : CLDX-US : December 19, 2016
Dec-15-16 02:51PM  Celldex Therapeutics, Inc.'s Biggest Failure in 2016 at Motley Fool
Dec-14-16 04:09PM  CELLDEX THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure, F
04:01PM  Celldex Therapeutics Announces Appointment to Board of Directors GlobeNewswire
Dec-13-16 12:22PM  3 Cheap Healthcare Stocks You Can Buy Right Now at Motley Fool
Dec-11-16 12:06PM  Celldex Therapeutics, Inc.'s Biggest Win in 2016 at Motley Fool
Dec-10-16 07:32PM  Is Celldex Therapeutics, Inc. (CLDX) a Good Stock To Buy? at Insider Monkey
Dec-08-16 12:23PM  ETFs with exposure to Celldex Therapeutics, Inc. : December 8, 2016
Dec-07-16 11:12AM  Is Celldex Therapeutics (CLDX) Stock a Solid Choice Right Now?
10:01AM  Why Celldex Rallied 22% In November at Motley Fool
Dec-06-16 05:53PM  Why You Should (and Shouldn't) Buy Celldex Therapeutics, Inc. at Motley Fool
Dec-05-16 04:04PM  CELLDEX THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure, F +6.76%
04:01PM  Theresa LaVallee, Ph.D., Joins Celldex Therapeutics Senior Management Team GlobeNewswire
08:01AM  Celldex Presents Data on CDX-1140, a Novel CD40 Agonist Antibody for Hematologic and Solid Malignancies, at the American Society of Hematology (ASH) Annual Meeting GlobeNewswire
Dec-02-16 01:17PM  The Worst Biotech Stocks of 2016 at Motley Fool
Dec-01-16 07:32AM  Celldex Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : CLDX-US : December 1, 2016 -6.30%
Nov-29-16 04:05PM  CELLDEX THERAPEUTICS, INC. Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Unregistered Sale
04:01PM  Celldex Therapeutics Completes Acquisition of Kolltan Pharmaceuticals GlobeNewswire
08:17AM  Down 11.7%: Is Celldex Therapeutics Now a Buy? at Motley Fool
Nov-23-16 12:47PM  ETFs with exposure to Celldex Therapeutics, Inc. : November 23, 2016
Nov-22-16 10:27AM  Celldex Therapeutics, Inc. :CLDX-US: Earnings Analysis: Q3, 2016 By the Numbers : November 22, 2016
Nov-21-16 07:03AM  Ready to Get In on Biotech? Check Out These 3 Stocks at Motley Fool +5.64%
Nov-15-16 02:24PM  Celldex Cancer Drug Did Well in Early Trial (CLDX) at Investopedia
08:03AM  Celldex Stock Up on Positive Data on New Cancer Candidate
Nov-14-16 03:58PM  Why Celldex Therapeutics, Inc. Stock Jumped Higher Again Today at Motley Fool +13.89%
08:01AM  Celldex Presents Data on New Product Candidate, CDX-1140, a Novel CD40 Agonist Antibody GlobeNewswire
Nov-09-16 04:41PM  Why Celldex Therapeutics, Inc. Stock Tumbled 22% in October at Motley Fool +6.61%
03:45PM  Celldex (CLDX) Q3 Loss Narrower than Expected, Sales Beat
Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. Its drug candidates include glembatumumab vedotin, an antibody-drug that is in Phase IIb study for the treatment of triple negative breast cancer and a Phase II study for the treatment of metastatic melanoma; and Varlilumab, an immune modulating antibody that is in a Phase 1 study designed to enhance a patient's immune response against cancer. It also develops earlier stage drug candidates in clinical development, including CDX-1401, an immunotherapeutic for cancer indications; CDX-301, an immune cell mobilizing agent and dendritic cell growth factor; and CDX-014, an antibody-drug conjugate targeting renal and ovarian cancers. In addition, the company focuses on the discovery and development of antibody-based drugs targeting receptor tyrosine kinases, such as CDX-0158, a humanized monoclonal antibody currently in a Phase 1 dose escalation study in refractory gastrointestinal stromal tumors and other KIT positive tumors; and CDX-3379, a human monoclonal antibody, which has completed a Phase 1b study in patients with solid tumors. Celldex Therapeutics, Inc. has research collaboration and license agreements with Medarex, Inc.; Rockefeller University; University of Southampton; Amgen Inc.; Amgen Fremont; and Seattle Genetics, Inc. The company is headquartered in Hampton, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CATLIN AVERY WSr. VP & CFOSep 02Option Exercise2.8010,00028,00083,586Sep 07 12:59 PM
KELER TIBORExecutive VP & CSOSep 02Buy3.323,0009,96018,868Sep 06 01:04 PM
CATLIN AVERY WSr. VP & CFOJun 03Option Exercise3.0122,84768,81273,586Jun 06 08:26 AM